Bookmark and Share

Compound Summary for: CID 151164

peramivir

Also known as: AC1L45SI; CHEMBL332608; 330600-85-6; 1A5BB290; SureCN99346; SureCN125439; AKOS015924549; AM84803; DB06614
Molecular Formula: C15H28N4O4   Molecular Weight: 328.40722   InChIKey: XRQDFNLINLXZLB-GKWMMFDUSA-N
Peramivir is an experimental antiviral drug being developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir is supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability. BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show first sub-section only
Literature
Patents
Biomolecular Interactions and Pathways
Classification
Chemical and Physical Properties
_ _